Drugs approved for the treatment of multiple sclerosis: review of their safety profile

References

• Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Živković M, Kolaković A, Stojković L, et al. Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis. J Neurol Sci. 2016 Apr 15;363:29–32.
   PubMed Web of Science ®Google Scholar
• Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19:S15–S20.
   PubMed Web of Science ®Google Scholar
• Poser CM, Brinar VV. The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology. 2007;29(3–4): 150–155. Epub 2007 Nov 27.
   PubMed Web of Science ®Google Scholar
• Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013 Feb;19(2 Suppl):S15–S20.
   PubMed Web of Science ®Google Scholar
• Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014 Aug 8;10:447–458. Epub 2014 Jul 8. Review. Erratum in: Nat Rev Neurol. 2014 Aug;10(8):i.
   PubMed Web of Science ®Google Scholar
• Galetta SL, Villoslada P, Levin N, et al. Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Bourdette DN, Ahmed SM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015 May 26;84(21):2185–2192.
   PubMed Web of Science ®Google Scholar
• Brunton LL. Immunomodulators. In: Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York (NY): McGraw-Hill Medical; 2005. p. 1424–1427.
   Google Scholar
• Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013 Feb;19(2 Suppl):S21–7. Review.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. Pharmacy and Therapeutics 37.3 (2012):175–184.  .
   Google Scholar
• Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert OpinBiolTher. 2008 Sep;8(9):1435–1447.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Plosker GL. Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs. 2011 Jan;25(1):67–88. doi:.
   PubMed Web of Science ®Google Scholar
• Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011 Jun 1;25(6):491–502.
   PubMed Web of Science ®Google Scholar
• Cree BAC. Multiple sclerosis. In: Brust JCM, editors Current diagnosis and treatment in neurology. New York (NY): Lange Medical Books/McGraw-Hill Medical; 2007.
   Google Scholar
• Hauser SL, Goodwin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 17th ed. II New York (NY): McGraw-Hill Medical; 2008. p. 2611–2621.
   Google Scholar
• Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: differences among products. J Neurol. 2004 Jun;251(Suppl 2):II15–II24.
   PubMedGoogle Scholar
• Kappos L, Freedman MS, Polman CH, et al. Effect of early vs delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:89–97.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentrestudy. Lancet Neurol. 2009 Oct;8(10):889–897.
   PubMed Web of Science ®Google Scholar
• Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr;26(4):827–838.
   PubMed Web of Science ®Google Scholar
• Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005;12:649–656.
   PubMed Web of Science ®Google Scholar
• Goeb JL, Even C, Nicolas G, et al. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006 Apr;21(3):186–193. Epub 2005 Dec 28.
   PubMed Web of Science ®Google Scholar
• Barbour T, Johnson S, Cohney S, et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012 Jul;27(7):2673–2685.
   PubMed Web of Science ®Google Scholar
• Vosoughi R, Marriott JJ. Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases. Mult Scler Relat Disord. 2014 May;3(3):321–325.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010 Aug 20;70(12):1545–1577.
   PubMed Web of Science ®Google Scholar
• Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825–850.
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller AI, Slagle S. A placebo controlled, double blinded, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991;41:533–539.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268–1276.
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatorytherapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. MultScler. 2010 Mar;16(3):342–350.
   Google Scholar
• Cree BAC. Multiple sclerosis. In: Brust JCM, editors Current diagnosis and treatment in neurology. New York (NY): Lange Medical Books/McGraw-Hill Medical; 2007.
   Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):705–713.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Dwyer MG, Ramasamy DP, et al. The effect of three times a week glatiramer acetate on cerebral T1 hypointense lesions in relapsing-remitting multiple sclerosis. J Neuroimaging. 2015 Nov–Dec;25(6):989–995.
   PubMed Web of Science ®Google Scholar
• Jancic J, Nikolic B, Ivancevic N, et al. Multiple sclerosis in pediatrics: current concepts and treatment options. Neurol Ther. 2016 Dec;5(2):131–143. Epub 2016 Sep 17. Review.
   PubMed Web of Science ®Google Scholar
• Chan A, Lo-Coco F. Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology. 2013 Apr 16;80(16):1529–1533. Review.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18(6):379–396.
   PubMed Web of Science ®Google Scholar
• Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. ClinTher. 2006 Apr;28(4):461–474.
   Google Scholar
• Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet. 2002 Dec 21–28;360(9350):2018–2025.
   PubMed Web of Science ®Google Scholar
• Rivera VM, Jeffery DR, Weinstock-Guttman B, et al. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013 Jul 11;13:80.
   PubMed Web of Science ®Google Scholar
• Mortensen SA, Olsen HS, Baandrup U. Chronic anthracyclinecardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J. 1986;55:274–282.
   PubMedGoogle Scholar
• Paul F, Dörr J, Würfel J, et al. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):198–200.
   PubMed Web of Science ®Google Scholar
• Dörr J, Bitsch A, Schmailzl KJ, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009 Sep 22;73(12):991–993.
   PubMed Web of Science ®Google Scholar
• Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012 Mar;5(2):75–79.
   PubMed Web of Science ®Google Scholar
• Buttmann M, Seuffert L, Mäder U, et al. Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study. Neurology. 2016 Jun 7;86(23):2203–2207.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013 Sep;73(13):1463–1481.
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. TYSABRI 300 mg concentrate for solution for infusion. European Medicine Agency. Biogen Idec Limited, UK:2016.
   Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med. 2010;61:35–47.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–368.
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924–933.
   PubMed Web of Science ®Google Scholar
• Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014 Apr 4;5:25–33.
   PubMedGoogle Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014 Dec;76(6):802–812.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kinoshita M, Foley JF, et al. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol. 2015;262:781–782.
   PubMed Web of Science ®Google Scholar
• Procedure No. EMEA/H/C/000603/II/0059/G. [Cited 2017 Oct 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report__Variation/human/000603/WC500148205.pdf.
   Google Scholar
• TYSABRI® (natalizumab): PML in Patients Receiving TYSABRI (USA TYSABRI PML Update). [cited 2017 Oct 10]. Available from: https://medinfo.biogen.com/secure/download?doc=workspace%3A%2F%2FSpacesStore%2Fded9df8f-d785-444a-ae89-888bef72aa7e&type=pmldoc&path=null&dpath=null&mimeType=null
   Google Scholar
• Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015;2015:809252.
   PubMedGoogle Scholar
• Schwab N, Schneider-Hohendorf T, Pignolet B, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. NeurolNeuroimmunolNeuroinflamm. 2016 Jan 27;3(1):e195.
   Google Scholar
• Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate–modifiers of lymphocyte migration. N Engl J Med. 2006;355:1088–1091.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Ontaneda D, Cohen JA. Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev ClinPharmacol. 2011;4:567–570.
   PubMedGoogle Scholar
• Summary of Product Characteristics. GILENYA 0.5 mg hard capsule. European Medicine Agency. Novartis Europharm Limited. UK. 2015.
   Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Aguiar C, Batista S, Pacheco R. Cardiovascular effects of fingolimod: relevance, detection and approach. Rev Port Cardiol. 2015 Apr;34(4):279–285.
   PubMedGoogle Scholar
• Cohen J, Von Rosenstiel P, Gottschalk R, et al. Long-term safety of fingolimod: an interim analysis of the LONGTERMS cohort. Neurol. 2015;84:S4.0006.
   Google Scholar
• Ziemssen T, Kern R, Cornelissen C. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol. 2015 Jun 18;15:93.
   PubMed Web of Science ®Google Scholar
• Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016 Mar;9(2):130–147.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Haden-Pinneri K, Memon NB, et al. Sudden unexpected death on fingolimod. MultScler. 2012 Oct;18(10):1507–1508.
   Google Scholar
• US Food Drug Administration. FDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). [cited 2017 Oct 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm.
   Google Scholar
• Gilenya: product information as approved by the CHMP on 19 April 2012, pending endorsement by the European Commission. [Cited 2017 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/04/WC500125687.pdf
   Google Scholar
• AIFA. Italy. 2015. [Cited 2017 Oct 10]. Available from: http://www.aifa.gov.it/sites/default/files/Pillola%20n.%20759%20-%2023-04-2015.pdf.
   Google Scholar
• EMA. Europe. 2015. [Cited 2017 Oct 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1#1.
   Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012 Feb 28;78(9):672–680.
   PubMed Web of Science ®Google Scholar
• Dinkin M, Paul F. Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect? Neurology. 2013 Jan 8;80(2):128–129.
   PubMed Web of Science ®Google Scholar
• Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology. 2013 Jan 8;80(2):139–144.
   PubMed Web of Science ®Google Scholar
• Li V, Kane J, Chan HH, et al. Continuing fingolimod after development of macular edema: a case report. Neurol Neuroimmunol Neuroinflamm. 2014 May 15;1(2):e13.
   PubMedGoogle Scholar
• Gross CM, Baumgartner A, Rauer S, et al. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology. 2012;79(19):2006–2007.
   PubMed Web of Science ®Google Scholar
• Avasarala J, Jain S, Urrea-Mendoza E. Approach to Fingolimod-induced lymphopenia in multiple sclerosis patients: do we have a roadmap? J Clin Pharmacol. 2017 May 25.
   PubMed Web of Science ®Google Scholar
• Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012 Feb;18(1):1–11.
   PubMed Web of Science ®Google Scholar
• Sinnecker T, Othman J, Kühl M, et al. Progressive multifocal Leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. Case Rep Neurol Med. 2016;2016:5876798.
   PubMedGoogle Scholar
• Gyang TV, Hamel J, Goodman AD, et al. Fingolimod-associated PML in a patient with prior immunosuppression. Neurology. 2016 May 10;86(19):1843–1845.
   PubMed Web of Science ®Google Scholar
• Warnke C, Olsson T, Hartung HP. PML: the dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci. 2015 Dec;36(12):799–801.
   PubMed Web of Science ®Google Scholar
• Sartori A, Carle D, Freedman MS. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opin Pharmacother. 2014 May;15(7):1019–1027.
   PubMed Web of Science ®Google Scholar
• Warnke C, zuHörste GM, Hartung H-P, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333–340.
   PubMed Web of Science ®Google Scholar
• Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. ActaNeurolScand. 2011;124:75–84.
   Google Scholar
• Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. TherAdv Chronic Dis. 2013 Sep;4(5):192–205.
   PubMedGoogle Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–1303.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomized, controlled phase 3 trial. MultScler. 2014 May;20(6):705–716.
   Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neur. 2014 October;13(10):p977–986.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;251:261–268.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Phillips JT, Fox R, Selmaj K, et al. Safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing–remitting multiple sclerosis (RRMS): interim results from ENDORSE Extension Study (P01.162). Neurology. 2013;80(MeetingAbstracts 1):P01.162.
   Google Scholar
• Ermis U, Weis J, Schulz JBN. PML in a patient treated with fumaric acid. Engl J Med. 2013 Apr 25;368(17):1657–1658.
   PubMed Web of Science ®Google Scholar
• Van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. MPN Engl J Med. 2013 Apr 25;368(17):1658–1659.
   PubMed Web of Science ®Google Scholar
• Baharnoori M, Lyons J, Dastagir A, et al. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e274.
   PubMed Web of Science ®Google Scholar
• EMA. Europe. 2014. [Cited 2017 Oct 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/11/news_detail_002206.jsp&mid=WC0b01ac058004d5c1.
   Google Scholar
• Lundy SK, Wu Q, Wang Q, et al. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 3;3(2):e211.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, et al. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76.
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Klinsing S, et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015 Dec 10;3(1):e183.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Ramsbottom MJ, Cantoni C, et al. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler. 2016 Jul;22(8):1061–1070. Epub 2015 Oct 12.
   PubMed Web of Science ®Google Scholar
• Losavio FA, Lucchini M, De Fino C, et al. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Mult Scler Relat Disord. 2016;7:68–69.
   PubMed Web of Science ®Google Scholar
• Muñoz MA, Kulick CG, Kortepeter CM, et al. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler. 2017;1:1352458516688351.
   Google Scholar
• Ma BB, Ostrow LW, Newsome SD. Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e203.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015Jan-Dec;1.
   PubMedGoogle Scholar
• Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. [ cited 2017Oct 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002423.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. [Cited 2017 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/10/WC500196017.pdf
   Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128(2):260–270.
   PubMed Web of Science ®Google Scholar
• Ruck T, Bittner S, Wiendl H, et al. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J MolSci. 2015 Jul;16(7):16414–16439.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. CARE-MS II investigators. Lancet. 2012 Nov 24;380(9856):1829–1839.
   PubMed Web of Science ®Google Scholar
• Fernandez Ó. Alemtuzumab in the treatment of multiple sclerosis. J Inflamm Res. 2014;7:19–27.
   PubMedGoogle Scholar
• Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015 Jan;8(1):31–45.
   PubMed Web of Science ®Google Scholar
• Ibitoye R, Wilkins A. Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol. 2014 Sep;261(9):1828–1829.
   PubMed Web of Science ®Google Scholar
• Gross CC, Ahmetspahic D, Ruck T, et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289.
   PubMed Web of Science ®Google Scholar
• De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194.
   PubMed Web of Science ®Google Scholar
• Obermann M, Ruck T, Pfeuffer S, et al. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Aug;22(9):1235–1241.
   PubMed Web of Science ®Google Scholar
• Ranganathan U, Kaunzner U, Foster S, et al. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Mult Scler. 2017 Mar 1:1352458517699876.
   Google Scholar
• Brownlee WJ, Chataway J. Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome. Mult Scler. 2017 May;23(6):876–877.
   PubMed Web of Science ®Google Scholar
• Berger T, Elovaara I, Fredrikson S, et al. Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs. 2017 Jan;31(1):33–50.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomized, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657–665.
   PubMed Web of Science ®Google Scholar
• Milo R. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2014 Jan;7(1):7–21.
   PubMed Web of Science ®Google Scholar
• Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17:604–619.
   PubMed Web of Science ®Google Scholar
• Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. SciTransl Med. 2012;4:145ra106.
   Google Scholar
• Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl AcadSci U S A. 2004 Jun 8;101(23):8705–8708.
   PubMed Web of Science ®Google Scholar
• Rose J, Watt H, White A, et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56:864–867.
   PubMed Web of Science ®Google Scholar
• Burns J, Bjorklund J, Klein J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69:785–789.
   PubMed Web of Science ®Google Scholar
• Bielekova Kova B, Richert N, Herman M, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology. 2011;77:1877–1886.
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381–390.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K et al. (2013) The safety and efficacy of daclizumab HYP in relapsing-remitting multiple sclerosis in the SELECTION extension study: primary results. In: 65th Annual Meeting of the American Academy of Neurology; 16–23 March 2013; San Diego, CA, abstract S01.00.
   Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015 Oct 8;373(15):1418–1428.
   PubMed Web of Science ®Google Scholar
• Elkins J, Sheridan J, Amaravadi L, et al. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(2):e65.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016 Sep;9:36–46.
   PubMed Web of Science ®Google Scholar
• Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosistherapies. Acta Neurol Scand. 2017 Sep;136(3):168–186.
   Web of Science ®Google Scholar
• Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016 Mar 1;86(9):847–855.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016 Nov 15;87(20):2074–2081. Epub 2016 Oct 19.
   PubMed Web of Science ®Google Scholar
• Barra ME, Soni D, Vo KH, et al. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016 Oct 9;2:2055217316672100.
   Google Scholar
• Von Büdingen HC, Bischof A, Eggers EL, et al. Onset of secondary progressive MS after long-term rituximab therapy - a case report. Ann Clin Transl Neurol. 2016 Dec 20;4(1):46–52.
   PubMed Web of Science ®Google Scholar
• Clavel G, Moulignier A, Semerano L. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine. 2017 Mar 18:pii:S1297-319X(17)30041-6.
   PubMed Web of Science ®Google Scholar
• Savic RM, Novakovic AM, Ekblom M, et al. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017 Mar 2;56:1245–1253.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e158.
   PubMed Web of Science ®Google Scholar